FY26 interim results presentation

11 November 2025

Richard Tyson, CEO

Paul Fry, CFO

Proactive response to H1 disruption and strong strategic progress

Strong strategic execution laying foundation for future growth and margin expansion

Proactive response to Q1 disruption in Imaging & Analysis: tariffs recovered, manufacturing adjustments; orders recovery in Q2

25% order growth in Advanced Technologies as commercial customer strategy takes hold

New products reinforce our technology leadership in our structural growth markets

Strong balance sheet, share buyback programme to be extended by £50m to £100m total

A challenging H1 landscape met with an agile and proactive response

Tariffs and academic funding impact in Q1

Tariffs: direct impacts successfully mitigated; open order book repriced, customer uncertainty

Academic funding: US academic customer orders delayed by proposed funding cuts

US federal funding



An improving picture from Q2 with order momentum

Tariffs: adjusted manufacturing locations; rare earth challenge addressed through engineering innovation and sourcing

Academic funding: US federal funding normalising; cuts expected to be largely reversed; Exploring new funding sources and commercial customer base

Financial review

Paul Fry

CFO

FY26 Interim results

11 November 2025

Challenging H1 following global disruption; well positioned well for strong H2

£'m	H1 FY26	H1 FY25	% Growth	% OCC[1]
Order intake	205.2	204.9	+0.1%	+1.4%
Revenue	185.5	204.3	(9.2%)	(7.9%)
Gross margin	55.0%	55.4%	(40bps)	(20bps)
Adjusted operating profit	24.7	35.3	(30.0%)	(22.9%)
Adjusted operating margin	13.3%	17.3%	(400bps)	(280bps)
R&D expense % revenue	9.3%	9.3%		
Normalised cash conversion[2]	41%	44%		
Free Cash Flow[3]	0.2	(7.1)		
Adjusted EPS basic	33.0p	46.6p		(29.2%)
Interim dividend	5.4p	5.1p		+5.9%

- All financials presented for **continuing operations** (NanoScience classified as held for sale)
- Market turbulence beginning in Q4 FY25, accelerating in Q1 FY26 with new tariff policies, impacting order intake
- **Imaging & Analysis** division revenue most impacted by subdued order intake, with Belfast business most exposed
- **Advanced Technologies** order intake growing strongly, with accelerating order book yet to fully pull through to revenue, and shift towards larger, longer lead time systems
- **Gross margin consistent and overheads flat** versus H1 FY25
- **High operational leverage** leading to sharp drop through from revenue to Adjusted Operating Profit (AOP) and cash

[1]Organic constant currency [2] Normalised excludes Severn Beach investment and Yatton proceeds [3]Free cash flow before acquisitions or other corporate development

Revenue evolution – I&A impacted by disrupted order intake in Q1; AT orderbook in transition

Revenue (£'m)



- H1 revenue impacted by Q1 tariff related shipping delays and disrupted order intake
- **I&A** division OCC[1] decline of 8.5% driven by:
  - Broader **customer hesitancy** in converting opportunities to orders
  - Continued headwinds in healthcare and life sciences (-9.1%)
- **Advanced Technologies** division OCC decline of 6.2% driven by:
  - Some impact of timing delays to Q2 shipments
  - Consistently high order intake growth from Q4 FY25 yet to fully show up in revenue
  - Semiconductor **orderbook transition**:
    - Towards **larger, multi-chamber, commercial** customers mainly US and Europe
    - Leading to **higher average selling prices (ASP), longer lead times**
  - Early teens **growth expected H2**

[1] Organic constant currency, reflecting acquisition of FemtoTools from June 2024.

Imaging and Analysis

H1 revenue impacted by Q1 tariff-related shipping delays and disrupted order intake

Order intake (£'m)



Revenue (£'m)

Book to Bill = 1.06



H1 order intake by end customer type



[1]All growth rates shown OCC

Advanced Technologies

Continued strong order intake, with orderbook weighted to larger, longer lead time commercial systems

Order intake (£'m)



Book to Bill = 1.25

Revenue (£'m)



H1 order intake by end customer type



[1]All growth rates shown OCC

Adjusted operating profit evolution

- Group gross margin consistent at 55% OCC, through tariff re-pricing, operational efficiency and higher plasma ASPs
- Total absolute overheads marginally lower than H1 FY25, but ~280 bps higher as % of OCC revenue
- AOP margin decline direct result of revenue decline and FX headwind



	H1 FY26 AOP	H1 FY26 OCC Margin %	H1 FY26 Margin %	H1 FY25 Margin %
Imaging & Analysis	£23.7m	18.4%	17.1%	22.5%
Advanced Technologies	£1.0m	2.5%	2.1%	1.4%
OI Group	**£24.7m**	**14.5%**	**13.3%**	**17.3%**

Adjustments to statutory results

£'m	H1 FY26	H1 FY25	% Growth	% OCC[1]
Adjusted operating profit	**24.7**	**35.3**	(30.0%)	(22.9%)
Net Finance Income	0.7	0.7		
Adjusted profit before tax	**25.4**	**36.0**	**(29.4%)**	**(22.5%)**
Amortisation and impairment of acquired intangible assets	(4.2)	(4.7)		
Non-recurring items[1]	(2.1)	(0.7)		
Mark-to-market of currency hedges[2]	1.2	2.7		
Statutory profit before tax	**20.3**	**33.3**	**(39.0%)**	
Taxation	(5.2)	(7.9)		
Statutory profit after tax from continuing operations	**15.1**	**25.4**	**(40.6%)**	
Profit/(loss) from discontinued operations	(3.1)	(1.3)		
Profit/(loss) for the period	**12.0**	**24.1**		

- **No changes to definitions of adjusting items**
- Non-recurring items include:
  - Belfast restructuring costs (£2.0m)
  - Plasma relocation costs (£2.8m)
  - Profit on disposal of Yatton site of +£3.7m
- Normalised effective **adjusted tax rate** expected to be ~24.8% for full year
- **Discontinued operations** comprises all post-tax revenues and costs directly related to the NanoScience business, including transaction related costs
- NanoScience adjusted loss of £2.2m in H1

[1] Non-recurring items include a non-cash charge of £0.6m against the unwind of discount on FemtoTools contingent consideration which is recognised as financial expenditure. [2] Changes in valuation of hedging instruments

Cash flow – improved FCF versus H1 prior year; accelerating into FY27



Working capital profile reflects:

- Inventories - finished goods shipments and materials build for H2 acceleration
- Other - typical H1 profile; down £7m (11%) versus H1 PY

- **Expecting strong FY27 cash generation:**
  - **Capital expenditure** reducing post-Severn Beach, normalising to £8m-£10m pa
  - **Non-recurring** costs completing (FY26 £7m-£8m; FY27 not material)
  - **Pension payments** ceased as at end October (FY26 £5.25m; FY27 nil)
- **H1 closing net cash £45.1m**
  - **Share buyback** of £25.5m and dividend payment of £9.9m in H1
  - NanoScience **sale proceeds[2]** expected H2

[1] Capex includes proceeds of £4.8m from Yatton sale [2]Gross proceeds of £57m. Tax due on proceeds expected to be ~£4m, of which £3m expected to be paid in H2

Capital allocation priorities are unchanged; further £50m share buyback expected

OXFORD INSTRUMENTS

Organic investment

Driving growth and margin

E.g.
- R&D at 8%-9% of revenue
- Severn Beach; Regional build out

Dividends

Progressive, in line with underlying earnings

- FY24: 20.8p +6.7%
- FY25: 22.2p +6.7%
- **H1 FY26 5.4p +5.9%**

Inorganic

Compelling strategic and synergy case, exceeding returns hurdles

Priorities for excess cash

Share buybacks

Compelling case to create value for our individual shareholders

Current share buyback programme to be extended by a further £50m, to £100m[1]

[1] As at 31 October 2025 £31.9m of the buyback programme bas been completed

Guidance for FY26 and outlook – no change from October trading update

For continuing operations (excl. NanoScience):

Revenue

- I&A OCC H2 revenue flat on prior year, supported by Q2 orders flat on prior year
- AT OCC H2 revenue growing mid-teens – full order book for the year
- H2 FX headwind of ~£5m (FY ~£9m)
- Macro and tariff uncertainties remain

Adjusted operating profit (AOP)

- Operation leverage benefit from AT growth in H2
- Belfast related savings of ~£4m in H2 versus prior year[1]
- H2 projected FX headwind ~£3m (FY~£5.5m)[2]
- Full year OCC AOP expected to be broadly in line with prior year

AOP growth drivers versus H2 prior year (£'m)



[1]Full year impact versus FY25 expected to be ~£5-6m [2]Overseas earnings USD dominated. Assuming GBP:USD rate 1.34. A USD 1 cent movement = ~£0.2m operating profit impact

Strong progress on strategic actions

Richard Tyson

CEO

FY26 Interim results

11 November 2025

Tariff-related disruption and lower orders in Q1; recovering momentum from Q2

Imaging & Analysis

Leading range of microscopy, scientific cameras, spectroscopy and associated analytical tools and software

H1 FY26

Orders	Revenue	Margin
£146.6m	£138.9m	17.1%

Medium-term target

Revenue	Margin
4-6%+ CAGR	22-24%

- Short-term demand impacts in core markets; medium-term prospects remain exciting
- Q1 orders impacted by global trading environment; Q2 in line with prior year, demand stabilising
- Agile and customer-focused response to tariffs: order book repriced, footprint adjustments complete in H2
- Material positive impact on H2 margin expected from self-help actions in Belfast as well as usual seasonality



Structural growth drivers remain strong in **Imaging & Analysis**

OXFORD INSTRUMENTS
Imaging & Analysis

Positioned in structurally growing markets

	Medium-term CAGR **	% of divisional revenue	% change in revenue YOY	
Materials Analysis	4-7%	55%	(7%)	Expanded product range driving increased market penetration; continued sustainable growth expected
Semiconductors	6-9%	16%	(10%)	Expanding product manufacturing lines across US, Europe and Asia; applications across lifecycle
Healthcare & Life Science	8-12%	22%	(9%)	Market remains weak but steadying; positive book-to-bill; order growth in US and rebuilding OEM portfolio

Globally diversified

- Globally diversified business, opportunity in all regions.
- US weighting increasing with resilient growth in H1 and as China reduces to c.20%
- Medium term demand drivers remain strong across all markets driven by technology
- Positive book-to-bill in life science
- Investment to localise key infrastructure and supply chains supports larger opportunity pipelines

* Other markets, including quantum and fundamental science, constitute remaining 7% of divisional revenue (£10m,-1%). Orders in other markets were up 66% CC, primarily driven by quantum

**Market growth opportunities refer to applied R&D and production and testing; Source: SDi/Gartner

Actions taken to add resilience and optionality for customers

Imaging & Analysis

Made in China: protecting market share, creating opportunity

China for China strategy: New electron microscopy detector assembly

Made in Germany: dual AFM production in US and Germany



Ulm site building atomic force microscopes for customers in China and Europe

Adapted footprint brings **greater flexibility** for **customers** and **Oxford Instruments**

Spotlight on USA: a good performance in an unpredictable environment

Orders **+11%** CC

- Strong recovery from disrupted Q1
- Growth underpinned by commercial customers
- Strong pipeline and focus on new and expanded sources of funding
- Service revenue up 9% year on year

OXFORD INSTRUMENTS
Imaging & Analysis

Comprehensive set of actions taken to improve business performance and returns

Rightsizing of workforce: 20% reduction completed in H1

Operational programme improving lead times, product quality, and productivity

Focus on rebuilding relationships driving growth in OEM orders and pipeline

Product line restructure and launches targeting increased margin and market share

Tangible outcomes include:

Benefit of c.**£4m** cost base reduction to flow through in H2

Inventory reduction: **£4m** vs **£2.5m** target

60% productivity gain

Extending our reach with cutting-edge, user-friendly instruments and software

OXFORD INSTRUMENTS
Imaging & Analysis

Simpler interfaces, faster results, improved capabilities

Budget-friendly atomic force microscope extends customer reach and margin

Simpler interface: no need to be an expert to generate high-quality images

Nuclear magnetic resonance technology leadership secured with two launches in 2025

New X-Pulse 90 benchtop instrument

New NMR instrument installed at GSK pre-launch for pharma packaging

Scientific camera innovation unlocking new capabilities for Oxford

First products launched from First Light Imaging: high speed and UV editions

Applications include semiconductor life science, quantum and astronomy



New Raman system enables greater speed and flexibility than ever

Improved light transmission and automation

Maintaining leadership through **continued R&D investment** at target levels of **8-9% of revenue**

Strong order growth driven by AI and augmented reality; revenue fully covered for the year

Advanced Technologies

Compound semiconductor fabrication equipment and X-ray technology

H1 FY26

Orders	Revenue	Margin
£58.6m	£46.6m	2.1%

Medium-term target

Revenue	Margin
10%+ CAGR	10-12%

- Strong positive momentum in compound semiconductor business driven by commercial customers
- Full order book to support another year of strong growth and margin improvement
- New site fully operational with new clean room supporting increased volume of customer demonstrations; capacity to scale as revenue grows
- Double digit market growth supporting exciting opportunity

* At constant currency

State-of-the art facility and focus on commercial sector underpin strong order growth

Leading expertise in **fabrication** and **process development** positions us to access **10%+ market growth** in **compound semiconductor**	**25%** order growth underpinned by **growth in commercial customers**	**Full order book** for FY26 supports confidence in full year **revenue growth** and **margin enhancement**
World class **clean room fully installed** and operational; new site capacity provides scope to double revenue	**Tier 1** European and US **commercial customers investing** in datacentres, AI and AR	New site and product streamlining increasing productivity: **12% labour efficiency** uplift YTD

Our role in the AI ecosystem of today and tomorrow

Specialist expertise in critical layer applications for AI, datacentres, quantum and augmented reality **attracting major technology players** and **boosting average system price**

Enabling today's hyperscale datacentres

Providing solutions for fabrication of opto (laser) devices for next gen data transfer rates

Supporting tomorrow's datacentre developments



Developing gallium nitride applications for reduced power consumption

Playing a key role in quantum technology transition

Supporting qubit fabrication, quantum sensing and communications

Accelerating augmented reality roadmaps

Active in developing multiple elements of augmented reality glasses *(see right)*



Accelerating development of augmented reality applications with global technology companies

Continued progress towards medium-term targets

- Imaging & Analysis self-help driving cost efficiencies and maintaining gross margin
- Strong double digit order growth expanding reach into commercial customers in Advanced Technologies
- Continuing progress on operational excellence programme, now expanding to our other UK sites
- 9.3% revenue invested in R&D with range of products launched this year
- Sale of NanoScience supports improved margin and ROCE
- Cash conversion expected to return to target levels
- Strong balance sheet, and current share buyback programme to be extended by a further £50m to £100m

OXFORD INSTRUMENTS

Proactive response to Q1 disruption; stronger H2 expected

Stronger H2 expected as benefits of actions taken flow through to revenue, profit and margin

Compound semiconductor strategy delivering strong order growth from commercial customers

Strong balance sheet, and share buyback extended

Strong strategic execution laying foundation for future growth and margin expansion

OXFORD INSTRUMENTS

Q&A